Strengthening the pipeline through 3 pillars: in-house drug discovery, in-licensing and PLCM
First written in FY2016. 4 of 10 entries say "Restated". Latest entry: FY2026.
11 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In the pharmaceutical business, we will select the optimal modalities from small molecules, nucleic acids and gene therapies, concentrate management resources on diseases and areas with global commercial potential, including hematology and intractable and rare diseases, and promote in-house drug discovery while also using open innovation to complement technologies and accelerate development. By focusing on in-licensing to the same extent as in-house drug discovery and advancing clinical development rapidly, including product life-cycle management (PLCM), we aim to launch an average of at least 2 new products per year.」
While maintaining the target of launching an average of at least 2 products per year, the Company has specified its selection of modalities, including gene therapy, use of open innovation and concentration on areas with global commercial potential. - 2026-05-29RestatedGeneral Meetings of Shareholders
「低分子・核酸・遺伝子治療から最適なモダリティを選択し、血液内科領域、難病・希少疾患領域などグローバル展開を狙える疾患・領域に経営資源を集中させ、技術の補完およびスピードアップのためオープンイノベーションも活用して自社創薬を推進します。導入にも自社創薬と同等に注力して、PLCM も含め、迅速に臨床開発を進めることで、年平均 2 品目以上の新製品の上市を目指します。」
自社創薬・導入・PLCM、モダリティ選択、オープンイノベーション、年平均2品目以上の上市目標を再掲している。 - FY2025RestatedAnnual report
「In the pharmaceutical business, we will focus on nucleic acid and small-molecule drug discovery, concentrate management resources on diseases and areas with global commercial potential, including hematology and intractable and rare diseases, and promote in-house drug discovery while also using open innovation to complement technologies and accelerate development. By focusing on in-licensing to the same extent as in-house drug discovery and advancing clinical development rapidly, including product life-cycle management (PLCM), we aim to launch an average of at least 2 new products per year.」
While maintaining the target of launching an average of at least 2 products per year through in-house drug discovery, in-licensing and PLCM, the Company has specified its concentration of management resources on nucleic acid and small-molecule drug discovery, open innovation and areas with global commercial potential. - FY2024RaisedAnnual report
「By focusing on in-licensing to the same extent as in-house drug discovery and advancing clinical development rapidly, including PLCM, we aim to launch an average of at least 2 new products per year.」
The Company explicitly states its degree of focus on in-licensing and the acceleration of clinical development as part of its pipeline expansion through in-house drug discovery, in-licensing and PLCM, and sets a target of launching an average of at least 2 products per year. - FY2023RestatedAnnual report
「In research and development, we will enhance our R&D pipeline through in-house drug discovery, including new modalities, in-licensing and product life-cycle management (PLCM), while continuing to launch new products in the market.」
The Company has reaffirmed its plan to strengthen the pipeline and launch new products through in-house drug discovery with a view to new modalities, in-licensing and PLCM. - FY2021RestatedAnnual report
「In research and development, we will enhance our R&D pipeline through in-house drug discovery, including new modalities, in-licensing and product life-cycle management (PLCM), while continuing to launch new products in the market.」
The Company has reaffirmed its plan to strengthen the pipeline through in-house drug discovery with a view to new modalities, in-licensing and PLCM. - FY2019ReframedAnnual report
「In research and development, we will enhance our R&D pipeline through in-house drug discovery, including new modalities, in-licensing and product life-cycle management (PLCM), while continuing to launch new products in the market.」
In addition to the previous 3 pillars of in-house drug discovery, in-licensing and PLCM, the direction of in-house drug discovery with a view to new modalities has been added. - FY2017AdvancedAnnual report
「• In March 2017, NS-917, a treatment for relapsed or refractory acute myeloid leukemia, was licensed in from デルタフライファーマ株式会社 of Tokushima, Japan. • In March 2017, NS-73, a treatment for hepatic sinusoidal obstruction syndrome, and NS-87, a treatment for secondary acute myeloid leukemia, were licensed in from Jazz Pharmaceuticals of Ireland.」
Treatments for relapsed or refractory acute myeloid leukemia, hepatic sinusoidal obstruction syndrome and secondary acute myeloid leukemia were added to the pipeline through in-licensing activities. - FY2017-Q3AdvancedAnnual report
「NS-32, a high-dose intravenous iron preparation, was licensed in from PharmaCosmos in Denmark in December 2016, and Phase I trials began in January 2017.」
NS-32 was newly added to the pipeline through in-licensing activities, and Phase I trials began. - FY2016First statedAnnual report
「In research and development, we will use in-house drug discovery, in-licensing and product life-cycle management (PLCM) as our 3 pillars, launch new products, actively pursue in-licensing in addition to in-house drug discovery, and enhance our R&D pipeline.」
The 3 pillars of the R&D approach are explicitly identified, together with ongoing new product launches and in-licensing activities.